Clinical, cytogenetic, and molecular follow-up studies of CML patients with and without BCR-ABL PEMs who received imatinib treatment.

N: number of patients, PEMs: pre-existing mutations; IM: imatinib; CHR: complete hematological response; PHR: partial hematological response; CCyR: complete cytogenetic response; MCyR: major cytogenetic response; minor CyR: minor cytogenetic response; MMR: major molecular response.

N：患者数量（number of patients），PEMs：预先存在的突变（pre-existing mutations）；IM：伊马替尼（imatinib）；CHR：完全血液学应答（complete hematological response）；PHR：部分血液学应答（partial hematological response）；CCyR：完全细胞遗传学应答（complete cytogenetic response）；MCyR：主要细胞遗传学应答（major cytogenetic response）；minor CyR：轻微细胞遗传学应答（minor cytogenetic response）；MMR：主要分子学应答（major molecular response）。